MindMed has taken a significant step forward in the development of innovative treatments for Generalised Anxiety Disorder (GAD), announcing...
Read MoreBeckley Psytech has unveiled promising topline results from its Phase 2a study of ELE-101, a groundbreaking synthetic intravenous (IV)...
Read MoreMinoryx Therapeutics and Neuraxpharm Group have announced a significant breakthrough in the treatment of cerebral adrenoleukodystrophy (cALD) in paediatric...
Read MoreBayer has officially begun a Phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor designed to...
Read MoreEverest Medicines has announced groundbreaking results from its Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine kinase...
Read MoreTeva Pharmaceutical Industries has unveiled encouraging results from its Phase 3 SPACE study, highlighting the efficacy and safety of...
Read More